Literature DB >> 11441197

Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study.

A I del Sol1, K G Moons, M Hollander, A Hofman, P J Koudstaal, D E Grobbee, M M Breteler, J C Witteman, M L Bots.   

Abstract

BACKGROUND AND
PURPOSE: We determined the contribution of common carotid intima-media thickness (IMT) in the prediction of future coronary heart disease and cerebrovascular disease when added to established risk factors.
METHODS: We used data from a nested case-control study comprising 374 subjects with either an incident stroke or a myocardial infarction and 1496 controls. All subjects were aged 55 years and older and participated in the Rotterdam Study. Mean follow-up was 4.2 years (range, 0.1 to 6.5 years). We evaluated which correlates of coronary heart disease and cerebrovascular disease contribute to the prediction of either a new incident myocardial infarction or a stroke. Logistic regression modeling and the area under the receiver operating characteristic curve (ROC area) were used to quantify the predictive value of the established risk factors and the added value of IMT.
RESULTS: The ROC area of a model with age and sex only was 0.65 (95% CI, 0.62 to 0.69). Independent risk factors were previous myocardial infarction and stroke, diabetes mellitus, smoking, systolic blood pressure, diastolic blood pressure, and total and HDL cholesterol levels. These risk factors increased the ROC area from 0.65 to 0.72 (95% CI, 0.69 to 0.75). This model correctly predicted 17% of all subjects with coronary heart disease and cerebrovascular disease. When common carotid IMT was added to the previous model, the ROC area increased to 0.75 (95% CI, 0.72 to 0.78). When only the IMT measurement was used, the ROC area was 0.71 (95% CI, 0.68 to 0.74), and 14% of all subjects were correctly predicted. There was no difference in ROC area when different measurement sites were used.
CONCLUSIONS: Adding IMT to a risk function for coronary heart disease and cerebrovascular disease does not result in a substantial increase in the predictive value when used as a screening tool.

Entities:  

Mesh:

Year:  2001        PMID: 11441197     DOI: 10.1161/01.str.32.7.1532

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  55 in total

1.  Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile?

Authors:  Banerjee Arnab; Ghosh Biswadip; Pande Arindam; Mandal Shyamash; Ghosh Anirban; Palui Rajan
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

2.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

3.  Vascular biomarkers in the prediction of clinical cardiovascular disease: the Strong Heart Study.

Authors:  Mary J Roman; Jorge R Kizer; Lyle G Best; Elisa T Lee; Barbara V Howard; Nawar M Shara; Richard B Devereux
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

Review 4.  Clinical value of carotid intima-media thickness testing.

Authors:  Patrick J Devine; Daniel W Carlson; Allen J Taylor
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

5.  Atherosclerosis in Takayasu arteritis.

Authors:  E Seyahi; S Ugurlu; R Cumali; H Balci; N Seyahi; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

6.  Association between conventional risk factors and different ultrasound-based markers of atherosclerosis at carotid and femoral levels in a middle-aged population.

Authors:  Patrick Yerly; Nicolas Rodondi; Barathi Viswanathan; Walter Riesen; Pierre Vogt; Pascal Bovet
Journal:  Int J Cardiovasc Imaging       Date:  2012-09-27       Impact factor: 2.357

7.  Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study.

Authors:  Juho R H Raiko; Costan G Magnussen; Mika Kivimäki; Leena Taittonen; Tomi Laitinen; Mika Kähönen; Nina Hutri-Kähönen; Antti Jula; Britt-Marie Loo; Russell J Thomson; Terho Lehtimäki; Jorma S A Viikari; Olli T Raitakari; Markus Juonala
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2010-10

Review 8.  Statin treatment and progression of atherosclerotic plaque burden.

Authors:  Diederick E Grobbee; Michiel L Bots
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

10.  Risk factors for age-related maculopathy.

Authors:  Paul P Connell; Pearse A Keane; Evelyn C O'Neill; Rasha W Altaie; Edward Loane; Kumari Neelam; John M Nolan; Stephen Beatty
Journal:  J Ophthalmol       Date:  2009-09-06       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.